Frequency of Pathological Proteins (M-components) in 6,995 Sera from an Adult Population, Acta Medica Scandinavica. 24 avr, vol.179, issue.2, pp.235-282, 2009. ,
Prevalence of Monoclonal Gammopathy of Undetermined Significance, n engl j med, vol.8, 2006. ,
Neuropathies périphériques au cours des dysglobulinémies, EMC-Neurologie. janv, vol.8, issue.3, pp.1-14, 2011. ,
, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision, Journal of the Peripheral Nervous System. mars, vol.15, issue.1, pp.1-9, 2010.
Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies, Acta Neurologica Scandinavica, vol.85, issue.6, pp.383-90, 1992. ,
Prevalence of monoclonal protein in peripheral neuropathy, Neurology, 1981. ,
The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia: Comparative clinical, immunological and nerve biopsy findings, Journal of Neurology, vol.238, issue.7, pp.383-91, 1991. ,
Neuropathy associated with monoclonal gammopathies of undetermined significance, Annals of Neurology. juill, vol.30, issue.1, pp.54-61, 1991. ,
Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases, Journal of the Neurological Sciences. mai, vol.137, issue.2, pp.124-154, 1996. ,
Neurolymphomatosis: a clinicopathologic syndrome reemerges, Neurology, 1992. ,
DOI : 10.1212/wnl.42.6.1136
Polyneuropathy in paraproteinaemia, Journal of Neurology. août, vol.232, issue.4, pp.204-218, 1985. ,
DOI : 10.1007/bf00313781
Length dependence in polyneuropathy associated with IgM gammopathy, Annals of Neurology. févr, vol.59, issue.2, pp.365-71, 2006. ,
DOI : 10.1002/ana.20785
Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy Comparison of patients without and with monoclonal gammopathy, Neurology, 1993. ,
Polyneuropathy associated with monoclonal gammopathy of undetermined significance: A prospective study of the prognostic value of clinical and laboratory abnormalities, Brain, vol.117, issue.6, pp.1385-93, 1994. ,
The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies, Brain, vol.124, issue.10, pp.1968-77, 2001. ,
POEMS syndrome: Update on diagnosis, risk-stratification, and management: POEMS syndrome, American Journal of Hematology, vol.90, issue.10, pp.951-62, 2015. ,
DOI : 10.1002/ajh.24171
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24171
Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients, Amyloid. juin, vol.18, issue.sup1, pp.98-100, 2011. ,
CRYOGLOBULINAEMIC NEUROPATHY: A CLINICAL, MORPHOLOGICAL AND IMMUNOCY TOCHEMICAL STUDY OF 8 CASES, Brain, vol.111, issue.3, pp.541-52, 1988. ,
Plasma-Cell Dyscrasia and Peripheral Neuropathy with a Monoclonal Antibody to Peripheral-Nerve Myelin, The New England Journal Of Medecine, 1980. ,
DOI : 10.1056/nejm198009113031105
Myelin-Associated Glycoprotein Is the Antigen for a Monoclonal IgM in Polyneuropathy, Journal of Neurochemistry, vol.39, issue.5, pp.1261-1266, 1982. ,
, CHRONIC DEMYELINATING NEUROPATHY ASSOCIATED WITH BENIGN IGM PARAPROTEINAEMIA. Brain, vol.106, issue.1, pp.169-95, 1983.
Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.243, issue.1, pp.34-43, 1995. ,
Peripheral neuropathy in IgM monoclonal gammopathy and wäldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG-reactive serum monoclonal component, American Journal of Hematology. janv, vol.45, issue.1, pp.25-31, 1994. ,
Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy, Annals of Neurology, vol.36, issue.3, pp.416-440, 1994. ,
IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy, Neurosurgery & Psychiatry. déc, vol.88, issue.12, pp.1094-1101, 2017. ,
Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between Mprotein antibody activity and clinical/electrophysiological features in 40 cases, Muscle & Nerve. janv, vol.21, issue.1, pp.55-62, 1998. ,
The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia: Comparative clinical, immunological and nerve biopsy findings, Journal of Neurology, vol.238, issue.7, pp.383-91, 1991. ,
Peripheral neuropathy in macroglobulinemia Incidence and antigen-specificity of M proteins, Neurology, 1987. ,
Facteurs pronostiques des gammapathies monoclonales de signification indéterminée, vol.14, p.11, 2008. ,
Monoclonal gammapathy of undetermined significance and solitary plasmocytoma, Hematology/Oncology Clinics of North America. févr, vol.11, issue.1, pp.71-87, 1997. ,
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, European Journal of Haematology, vol.43, issue.S51, pp.70-75, 1989. ,
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, 33. on behalf of the International Myeloma Working Group22, vol.378, pp.1121-1128, 2010. ,
Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management: Update on Waldenström macroglobulinemia, American Journal of Hematology. avr, vol.90, issue.4, pp.346-54, 2015. ,
Peripheral neuropathies in Waldenstrom's macroglobulinaemia, Neurosurgery & Psychiatry. 1 févr, vol.77, issue.2, pp.224-232, 2006. ,
International prognostic scoring system for Waldenstrom macroglobulinemia, Blood. 30 avr, vol.113, issue.18, pp.4163-70, 2009. ,
, British Journal of Haematology. sept, vol.138, issue.6, pp.700-720, 2007.
Myelin-associated glycoprotein (MAG): past, present and beyond, Journal of Neurochemistry. 4 janv, vol.0, issue.0, p.070214184024009, 2007. ,
Immunocytological Studies of LMAG Expression Regulation during Myelination of Embryonic Brain Cell Cocultures, Developmental Neuroscience, vol.24, issue.6, pp.495-503, 2002. ,
Autoantibodies associated with peripheral neuropathy, Muscle & Nerve. juill, vol.22, issue.7, pp.800-822, 1999. ,
Myelin-associated glycoprotein and its axonal receptors, Journal of Neuroscience Research, vol.87, issue.15, pp.3267-76, 2009. ,
Expression and function of myelin-associated proteins and their common receptor NgR on oligodendrocyte progenitor cells, Brain Research. févr, vol.1437, pp.1-15, 2012. ,
MyelinAssociated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth, Neuron. juill, vol.35, issue.2, pp.283-90, 2002. ,
Identification of Myelin-Associated Glycoprotein as a Major Myelin-berived Inhibitor * n of Neurite Growth, Neuron, vol.7, 1994. ,
, pdf. Neuron, 1994.
Myelination in the absence of myelin associated glyocoprotein, Nature, 1994. ,
Complement dépendaent demyelination in patients with IgM monoclonal gammapathy and polyneuropathy, N Engl J Med ,
, Immunofluorescence study of patients with neuropathy and IgM M proteins, vol.18, pp.173-81, 1985.
AntiMAG and anti-SGPG antibodies in neuropathy, Muscle & Nerve. mai, vol.19, issue.5, pp.637-680, 1996. ,
Variability in the binding of antiMAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia, Journal of Neuroimmunology. mars, vol.95, issue.1-2, pp.174-84, 1999. ,
Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1, Nature, 1983. ,
Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients, Neurosurgery & Psychiatry. 1 juill, vol.61, issue.1, pp.36-42, 1996. ,
Tremor associated with benign IgM paraproteinaemic neuropathy, Brain, vol.119, issue.3, pp.789-99, 1996. ,
DOI : 10.1093/brain/119.3.789
URL : https://academic.oup.com/brain/article-pdf/119/3/789/1113136/119-3-789.pdf
Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features, Neurosurgery & Psychiatry. mai, vol.89, issue.5, pp.499-505, 2018. ,
Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies, Journal of Immunology Research, vol.2015, pp.1-9, 2015. ,
Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy, Journal of the Neurological Sciences. août, vol.319, issue.1-2, pp.75-80, 2012. ,
, ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10, vol.23, pp.924-957, 2013.
DOI : 10.1016/j.nmd.2013.06.006
URL : https://doi.org/10.1016/j.nmd.2013.06.006
Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies ,
Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies, International Journal of Neuroscience, vol.127, issue.5, pp.439-486, 2017. ,
DOI : 10.1080/00207454.2016.1191013
Distal acquired demyelinating symmetric neuropathy, Neurology. 8 févr, vol.54, issue.3, pp.615-615, 2000. ,
DOI : 10.1212/wnl.54.3.615
Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucurohyl paragloboside, vol.7, 1994. ,
Terminal latency index and modi®ed F ratio in distinction of chronic demyelinating neuropathies, Clinical Neurophysiology, vol.7, 2001. ,
Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?, Clinical Neurophysiology, vol.8, 2002. ,
DOI : 10.1046/j.1529-8027.2002.02032_1.x
Are electrophysiological features related to disability in patients with anti-MAG neuropathy?, Neurophysiologie Clinique/Clinical Neurophysiology. févr, vol.47, issue.1, pp.75-81, 2017. ,
, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision, Journal of the Peripheral Nervous System. mars, vol.15, issue.1, pp.1-9, 2010.
, European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies, Joint Task Force of the EFNS and the PNS, vol.15, pp.185-95, 2010.
Les autoanticorps IgM anti-MAG par Elisa Bühlmann : apport diagnostique dans 117 neuropathies périphériques auto-immunes associées à une IgM monoclonale à activité anti-SGPG/SGLPG, Ann Biol Clin, vol.64, p.7, 2006. ,
Les polyneuropathies avec IgM monoclonale anti-MAG : étude descriptive clinique, biologique, électrophysiologique et anatomopathologique d'une cohorte de 13 patients, Revue Neurologique. déc, vol.165, issue.12, pp.1071-1080, 2009. ,
Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance AntiYMyelin-Associated Glycoprotein Neuropathy, J Neuropathol Exp Neurol, vol.69, issue.11, p.15, 2010. ,
Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance AntiYMyelin-Associated Glycoprotein Neuropathy, J Neuropathol Exp Neurol, vol.69, issue.11, p.15, 2010. ,
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies ,
, Cochrane Database of Systematic Reviews, issue.4, 2016.
,
A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy, Annals of Neurology, vol.40, issue.5, pp.792-797, 1996. ,
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy, Journal of Neurology, vol.249, issue.10, pp.1370-1377, 2002. ,
Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.243, issue.1, pp.34-43, 1995. ,
Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy, Muscle & Nerve. juin, vol.24, issue.6, pp.778-86, 2001. ,
Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases, La Revue neurologique, 1993. ,
Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy, Neurosurgery & Psychiatry, vol.57, pp.46-55, 1994. ,
High-dose intravenous immunoglobulins in the treatment of demyelinating neuropathy associated with monoclonal gammopathy, Neurology, 1990. ,
Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy, Neurology. 1 févr, vol.48, issue.2, pp.321-329, 1997. ,
Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group, Journal of Neurology ,
Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance, N Engl J Med, 1991. ,
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy, Neurology. 3 juill, vol.69, issue.1, pp.50-59, 2007. ,
A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM, Neurosurgery & Psychiatry. 1 juill, vol.63, issue.1, pp.28-34, 1997. ,
A randomised double blind trial versus placebo does not confirm the benefit of á-interferon in polyneuropathy associated with monoclonal IgM, J Neurol Neurosurg Psychiatry ,
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy, Neurology. 11 juin, vol.80, issue.24, pp.2217-2242, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01085949
Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology. mars, vol.65, issue.3, pp.286-93, 2009. ,
Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy, Journal of the Neurological Sciences. juin, vol.377, pp.144-152, 2017. ,
Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG followup study: Long-term efficacy of rituximab in IgM, Journal of the Peripheral Nervous System. mars, vol.21, issue.1, pp.10-14, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01285408
Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies, Journal of Neurology. sept, vol.258, issue.9, pp.1717-1726, 2011. ,
DOI : 10.1007/s00415-011-5994-0
URL : https://hal.archives-ouvertes.fr/hal-00703179
Rituximab for polyneuropathy with IgM monoclonal gammopathy, Neurosurgery & Psychiatry. 1 sept, vol.80, issue.9, pp.1036-1045, 2009. ,
DOI : 10.1136/jnnp.2008.155325
Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System. juin, vol.12, issue.2, pp.102-109, 2007. ,
High-dose rituximab and anti-MAG-associated polyneuropathy, Neurology, 2006. ,
DOI : 10.1212/01.wnl.0000201193.00382.b3
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies, Muscle & Nerve. mai, vol.27, issue.5, pp.611-616, 2003. ,
Treatment of IgM antibody associated polyneuropathies using rituximab, Neurosurgery & Psychiatry. 1 avr, vol.74, issue.4, pp.485-494, 2003. ,
Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody, Journal of the Neurological Sciences. janv, vol.348, issue.1-2, pp.67-73, 2015. ,
Marked and sustained improvement on nerve conduction study of anti-myelin-associated glycoprotein neuropathy following rituximab therapy: Letters to the Editor, Muscle & Nerve. mars, vol.53, issue.3, pp.489-90, 2016. ,
Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy, Journal of the Neurological Sciences. févr, vol.373, pp.344-349, 2017. ,
Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy, Journal of the Neurological Sciences, vol.345, issue.1-2, pp.224-231, 2014. ,
DOI : 10.1016/j.jns.2014.07.055
Worsening after rituximab treatment in anti-mag neuropathy, Muscle & Nerve. sept, vol.32, issue.3, pp.378-387, 2005. ,
DOI : 10.1002/mus.20386
Clinical And Immunological Worsening In A Patient Affected With Waldenstrom Macroglobulinemia And Anti-Mag Neuropathy After Treatment With Rituximab, Haematologica, 2006. ,
Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment: Letter to the Editor, Journal of the Peripheral Nervous System. juin, vol.18, issue.2, pp.189-91, 2013. ,
Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide, Neurology. 1 août, vol.45, issue.8, pp.1577-80, 1995. ,
DOI : 10.1212/wnl.45.8.1577
Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance, Neurology, vol.47, issue.5, pp.1227-1260, 1996. ,
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine, Neurosurgery & Psychiatry. 1 mai, vol.66, issue.5, pp.575-80, 1999. ,
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy, Neurology, 2006. ,
Peripheral neuropathy in IgM monoclonal gammopathy and wäldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG-reactive serum monoclonal component, American Journal of Hematology. janv, vol.45, issue.1, pp.25-31, 1994. ,
Neuropathy with Predominant Small Fiber Involvement Associated with Abnormal Anti-MAG Titer, Internal Medicine, vol.49, issue.23, pp.2627-2636, 2010. ,
IgM MGUS antiMAG neuropathy with predominant muscle weakness and extensive muscle atrophy, Muscle & Nerve. sept, vol.42, issue.3, pp.433-438, 2010. ,
Prevalence, correlates and impact of pain and cramps in anti-MAG neuropathy: a multicentre European study, European Journal of Neurology. janv, vol.25, issue.1, pp.135-176, 2018. ,
Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy, Neurology. 1 févr, vol.52, issue.3, pp.498-498, 1999. ,
ENMG des neuropathies anti-MAG : intérêt diagnostique et corrélations cliniques, Neurophysiologie Clinique/Clinical Neurophysiology. juin, vol.47, issue.3, p.197, 2017. ,
Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology. mars, vol.65, issue.3, pp.286-93, 2009. ,
B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy, Neurosurgery & Psychiatry, vol.82, issue.11, pp.1291-1295, 2011. ,
Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies, International Journal of Neuroscience, vol.127, issue.5, pp.439-486, 2017. ,